[1] D'Amico G,Pagliaro L,Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis,1999,19:475-505. [2] 中华医学会肝病学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 临床肝胆病杂志, 2016,32:203-219. [3] Solà E,Lens S,Guevara M,et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension.Hepatology,2010,52: 1783-1790. [4] Yim SY,Seo YS,Jung CH,et al. Risk factors for developing hyponatremia during terlipressin treatment: a retrospective analyses in variceal bleeding. J Clin Gastroenterol,2015,49: 607-612. [5] Kim WR,Biggins SW,Kremers WK,et al. Hyponatremia and mortality among patients on the liver-transplant waiting list.N Engl J Med,2008,359: 1018-1026. [6] 顾勇,游淮舟,林善琰.水钠代谢紊乱//陈灏珠. 实用内科学.第12版.北京:人民卫生出版社,2005: 976-983. [7] Ioannou GN, Doust J, Rockey DC. Systematic review: Terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther,2003,17: 53-64. [8] Baik SK,Jeong PH,Ji SW,et al.Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.Am J Gastroenterol,2005,100: 631-635. [9] Machová A. Antidiuretic activity of terlipressin (triglycyl-lysine vasopressin)-role of pressure natriuresis. Physiol Res,1992,41: 121-127. [10] Kang YJ,Bae EJ,Hwang K,et al. Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis. Springerplus,2013,2: 519. [11] Krag A,Bendtsen F,Pedersen EB,et al. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol,2008,295: F1295-1300. [12] 叶欣, 金涛, 陈日坚,等. 渗透性脱髓鞘综合征12例临床分析. 广东医学, 2016, 37:108-110. [13] John S,Thuluvath PJ. Hyponatremia in cirrhosis:pathophysiology and management. World J Gastroenterol,2015,21: 3197-3205. [14] Seo YS,Park SY,Kim MY,et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology,2014,60: 954-963. |